Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasipimidine in insomnia disorder
NCT06956495Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tasipimidine in insomnia disorder, sponsored by Orion Corporation. Started Aug 2023; status: completed.
02
Drugs
tasipimidine
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT06956495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956495.